Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 4Q

Growth was driven by Tysabri sales, up 74% to $156 million in the quarter and up 156% to $589 million for the year.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

4Q Revenues: $1.1 billion (+20%)

4Q Earnings: $207.0 million (+3%)

FY Revenues: $4.1 billion (+29%)

FY Earnings: $783.0 million (+23%)

Comments: Growth was driven by Tysabri sales, up 74% to $156 million in the quarter and up 156% to $589 million for the year. In the quarter, Biogen recognized revenue of $156 million related to Tysabri, consisting of $53 million related to Elan sales in the U.S. and $103 million related sales in rest of world markets. Avonex sales were up 13% in the quarter to $565.8 million, and up 18% for the year to $2.2 billion. Rituxan revenues from the joint business arrangement with Genentech were $303 million in the quarter and $1.1 billion for the year. Royalties were $29 million in quarter (-12%) and $116 million for the year (+14%). R&D expenses were $293 million in the quarter (+28%) and $1.1 billion for the year (+16%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters